RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
more
Stories about Arzneimittel
Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
morePatientGPT from Semalytix Will Replace Six Months of Evidence & Insight Generation in Life Science with Seconds
moreEmpowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced
Brussels/Aachen (ots) - - Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. - The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. The European Pain Federation EFIC® and the ...
moreDEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
moreLTS Lohmann Therapie-Systeme AG
LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the ...
moreGenialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
moreSuccessful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
Munich / Paris / Tokyo (ots) - - Adragos Pharma now third largest pure-play CDMO in the Japanese market - Long-term agreement with Sanofi secures local healthcare supply Munich-based pharmaceutical contract manufacturer (CDMO) Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading ...
moreGerresheimer and Corning announce joint venture to meet growing demand for Velocity® Vials, accelerating the delivery of lifesaving treatments
Düsseldorf (ots) - Gerresheimer AG, the leading global provider of healthcare, beauty, and drug delivery systems for pharma, biotech, and cosmetics, today announced a joint venture with Corning Incorporated (NYSE: GLW), a leading innovator in materials science and manufacturing, to increase global access to the ...
moreUniversity of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients
Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...
moreEleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
moreePresentation of the results of the in-vitro study regarding the anti-proliferative and pro-apoptotic effects of Polyphenon® E (Veregen®) at the 31st German Skin Cancer Congress on 10 September 2021
Strausberg (ots) - Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract "Inhibition of cell-proliferation and cell viability by Polyphenon E ® (Veregen®) in cutaneous SCC cell lines" has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In ...
moreDid my vaccine work? New rapid test for the determination of vaccination success
moreEuropean Association of E-Pharmacies (EAEP)
EAEP as a Driving Force and Think Tank: European Association of Online Pharmacies Repositions Itself
Brussels/Berlin (ots) - The leading association of European online pharmacies has a new board team, a new name and a new external image: Walter Hess, Head Germany in the Group Management of the Zur Rose Group and CEO of DocMorris N.V., is now president of the association and Stefan Feltens, CEO SHOP APOTHEKE EUROPE, ...
moreMerger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis
moreEleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...
moreEleva's drug candidate to be examined for use in Covid-19 treatment
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...
moreElastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients
Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...
moreNew in-vivo study confirms that ciliate vaccine protects against flu
moreSysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...
moreEckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
moreNew UK sales subsidiary for Dr. Hauschka: WALA UK Ltd.
Bad Boll/Eckwälden (ots) - Dr. Hauschka, a brand marketed by the traditional German company WALA Heilmittel GmbH, is now able to boost its presence on the UK market. A newly established subsidiary, WALA UK Ltd., which is based in Oxfordshire near London, will be marketing and distributing the premium natural and organic cosmetics products as of 1 January. Dr. Hauschka enthusiasts will be able to find a wide range of ...
moreBoehringer Ingelheim's pramipexole (Sifrol(R)/Mirapexin(R)) Can Provide Benefit of Improved Mood Disturbance for People With Restless Legs Syndrome
GLASGOW, Scotland (ots) - - FOR HEALTHCARE JOURNALISTS (For media outside the US only) - New Data Shows pramipexole is an Effective Treatment Option for the Broad Range of RLS Symptoms During Both the Night and Daytime New data indicate that when treated with ...
more
1